Timeline

Olivier Leclercq

Research Engineer

27 Sep 2022

project

ANR Texleish: Targeting host-parasite interactions through the inhibition of excreted leishmania casein kinase 1

22 Sep 2022

project

Pasteur-Weizmann project: Role of kinases in vesicle-mediated regulation of host-pathogen interactions: Focus on Leishmania donovani and Plasmodium falciparum.

20 Sep 2022

project

Campus France procope: CASEIN KINASE 1, A KEY REGULATOR OF TUMORIGENESIS AND HOST-PATHOGEN INTERACTIONS

08 Feb 2022

team

Signalling and host-parasite interactions

15 Jan 2021

publication

In vitro identification of imidazo[1,2-a]pyrazine-based antileishmanial agents and evaluation of L. major casein kinase 1 inhibition.

01 May 2016

publication

From Drug Screening to Target Deconvolution: a Target-Based Drug Discovery Pipeline Using Leishmania Casein Kinase 1 Isoform 2 To Identify Compounds with Antileishmanial Activity.

14 Sep 2015

project

PTR 392 – Systems-wide analysis of Leishmania virulence

07 Sep 2015

project

FP7 Targeting the Leishmania kinome for the development of novel anti-parasitic strategies (LeishDrug)

07 Sep 2015

project

ANR TransLeish – Discovery of druggable protein kinases in the protozoan parasite Leishmania donovani using hit compounds identified by phenotypic screening

11 May 2015

team

Molecular Parasitology and Signaling

01 Sep 2014

publication

Transgenic analysis of the Leishmania MAP kinase MPK10 reveals an auto-inhibitory mechanism crucial for stage-regulated activity and parasite viability.

01 Jul 2014

publication

Probing druggability and biological function of essential proteins in Leishmania combining facilitated null mutant and plasmid shuffle analyses.

01 Jan 2014

publication

Pharmacological assessment defines Leishmania donovani casein kinase 1 as a drug target and reveals important functions in parasite viability and intracellular infection.

16 May 2013

publication

Enrichment of Leishmania donovani ATP-binding proteins using a staurosporine capture compound.

09 Aug 2012

publication

The crystal structure of the MAP kinase LmaMPK10 from Leishmania major reveals parasite-specific features and regulatory mechanisms.

26 Mar 2011

publication

Adaptation of a 2D in-gel kinase assay to trace phosphotransferase activities in the human pathogen Leishmania donovani.

29 Jun 2010

publication

Cyclosporin A treatment of Leishmania donovani reveals stage-specific functions of cyclophilins in parasite proliferation and viability.

23 Jan 2008

publication

A little guide for advanced search:

Timeline

ANR Texleish: Targeting host-parasite interactions through the inhibition of excreted leishmania casein kinase 1

Pasteur-Weizmann project: Role of kinases in vesicle-mediated regulation of host-pathogen interactions: Focus on Leishmania donovani and Plasmodium falciparum.

Campus France procope: CASEIN KINASE 1, A KEY REGULATOR OF TUMORIGENESIS AND HOST-PATHOGEN INTERACTIONS

Signalling and host-parasite interactions

In vitro identification of imidazo[1,2-a]pyrazine-based antileishmanial agents and evaluation of L. major casein kinase 1 inhibition.

From Drug Screening to Target Deconvolution: a Target-Based Drug Discovery Pipeline Using Leishmania Casein Kinase 1 Isoform 2 To Identify Compounds with Antileishmanial Activity.

PTR 392 – Systems-wide analysis of Leishmania virulence

FP7 Targeting the Leishmania kinome for the development of novel anti-parasitic strategies (LeishDrug)

ANR TransLeish – Discovery of druggable protein kinases in the protozoan parasite Leishmania donovani using hit compounds identified by phenotypic screening

Molecular Parasitology and Signaling

Transgenic analysis of the Leishmania MAP kinase MPK10 reveals an auto-inhibitory mechanism crucial for stage-regulated activity and parasite viability.

Probing druggability and biological function of essential proteins in Leishmania combining facilitated null mutant and plasmid shuffle analyses.

Pharmacological assessment defines Leishmania donovani casein kinase 1 as a drug target and reveals important functions in parasite viability and intracellular infection.

Enrichment of Leishmania donovani ATP-binding proteins using a staurosporine capture compound.

The crystal structure of the MAP kinase LmaMPK10 from Leishmania major reveals parasite-specific features and regulatory mechanisms.

Adaptation of a 2D in-gel kinase assay to trace phosphotransferase activities in the human pathogen Leishmania donovani.

Cyclosporin A treatment of Leishmania donovani reveals stage-specific functions of cyclophilins in parasite proliferation and viability.

Ectopic expression of AID in a non-B cell line triggers A:T and G:C point mutations in non-replicating episomal vectors.